Bo Zhu

Huaian First People’s Hospital — China

Medicine · Health Sciences

56h-index12.6kcitations341works6.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(60), Lung Cancer Treatments and Mutations(50), Immunotherapy and Immune Responses(45), Immune Cell Function and Interaction(29), Immune cells in cancer(25)

Publications341 total

Transformer-Based Deep Learning Model Using MRI-Derived Microvascular Atlas for Predicting Lymphovascular Invasion in Breast Cancer Patients
Technology in Cancer Research & Treatment·2026Open Access
Controllable diffusion framework for imbalanced Phi OTDR events classification
Scientific Reports·2025Open Access
The effect of social media use on language learning: A meta-analysis
System·2025
Stress hyperglycemia ratio modulates the impact of organ dysfunction on mortality risk in critically ill patients with atrial fibrillation: insights from the MIMIC-IV database
Cardiovascular Diabetology·2025Open Access
Ultrasound-assisted supercritical carbon dioxide extraction of lutein from Tropaeolum majus flowers
Food Chemistry·2025
Engineering magnetically guided bacteriophages for precision antimicrobial therapy and targeted biofilm eradication
2025Open Access
P3.12.07 Rezivertinib in EGFR-Mutated NSCLC Patients With Cns Metastases: Cns Efficacy From Phase 3 RAZOR Study
Journal of Thoracic Oncology·2025· 1 cited
Diagnosis and Treatment of Severe Acute Sepsis Caused by Burkholderia pseudomallei Infection: A Case Report and Literature Review
Infectious Microbes & Diseases·2025Open Access
Synergistic ultrasound-supercritical CO2 technology for flavonoids extraction from Toxicodendron vernicifluum (Stokes) F. A. Barkley
Industrial Crops and Products·2025· 1 citedOpen Access
2773P Patient-reported outcomes (PROs) from DeLLphi-304: The first phase III trial evaluating tarlatamab and chemotherapy (CTx) in patients (Pts) with previously treated small cell lung cancer (SCLC)
Annals of Oncology·2025
LBA101 Tarlatamab as second-line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free interval (CFI) and prior PD-(L)1 inhibitor use in the phase III DeLLphi-304 trial
Annals of Oncology·2025
Clinical and epidemiological analysis of 893 patients with spinal tuberculosis: an 11-Year investigation of a general hospital in East China
BMC Musculoskeletal Disorders·2025Open Access
Antibiotics and benthic fauna diversity affect nitrogen removal and greenhouse gas emissions in constructed wetlands by changing enzyme activity and microbial community
Bioresource Technology·2025· 2 cited
DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps
Cancer Cell·2025· 7 cited
Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.
Journal of Clinical Oncology·2025· 6 cited
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
New England Journal of Medicine·2025· 85 citedOpen Access
Effect of postpartum care model on the occurrence of postpartum depression
The Journal of Maternal-Fetal & Neonatal Medicine·2025· 1 citedOpen Access
Alexithymia in Functional Defecation Disorder: The Incidence and the Effect on Treatment
Journal of Digestive Diseases·2025
Exogenous TSG-6 treatment alleviates DSS-induced colitis in mice by modulating Pou2f3 and promoting tuft cells differentiation
Molecular Medicine·2025· 2 citedOpen Access
Φ-GLMAE: global-local masked autoencoder for Φ-OTDR event classification
Measurement Science and Technology·2025· 1 cited
page 1 of 18Next →

Frequent Co-authors

Haixia Long(11), Yongsheng Li(8), Qingzhu Jia(6), Tong Xiang(6), Yisong Y. Wan(5), Degao Chen(4), Xiao Han(4), Zhongyu Wang(4), Jiani Huang(4), Alistair L. J. Symonds(4), Ying Zhu(4), Zhihua Gong(3), Zhijie Wang(3), Jianguo Sun(3), Jie Wang(3), Yu‐zhong Duan(3), Rongkai Xie(3), Xiuming Xi(3), Bo Guo(3), Jianbao Gao(3)